Who is sponsoring NCT05256589?

NCT05256589 is sponsored by Sona Nanotech Inc.

What drugs are being tested in NCT05256589?

Interventions in NCT05256589: Sona Saliva C-19 Rapid Self-test.

What condition does NCT05256589 study?

NCT05256589 studies Sars-CoV-2 Infection.

Is NCT05256589 still recruiting?

NCT05256589 is currently completed. Last updated 24 March 2023.

Last reviewed 2023-03-24 · How we verify

NCT05256589

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Evaluation of the SONA Saliva C-19 Rapid Self-Test for the Detection of COVID-19

Completed NA Last updated 24 March 2023

What this trial tests

NA trial testing Sona Saliva C-19 Rapid Self-test in Sars-CoV-2 Infection in 500 participants. Completed in 19 May 2022.

Timeline

19 April 2022

Primary endpoint
26 April 2022

19 May 2022

Quick facts

Lead sponsor	Sona Nanotech Inc
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	500
Start date	19 April 2022
Primary completion	26 April 2022
Estimated completion	19 May 2022
Sites	1 location across Canada

Drugs / interventions tested

Sona Saliva C-19 Rapid Self-test

Conditions studied

Sars-CoV-2 Infection — all drugs for Sars-CoV-2 Infection →

Sponsor

Sona Nanotech Inc

Who can join

18 and older, any sex, with Sars-CoV-2 Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Sona Saliva C-19 Rapid Self-Test is a lateral flow assay intended for detection of the SARS-CoV-2 virus. Performance of the Sona Saliva C-19 Rapid Test assay will be assessed by comparison to an RT-PCR reference method.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Sars-CoV-2 Infection

Currently open trials in the same condition.

NCT06631287 — Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Sym · Phase 3 · recruiting
NCT04964115 — Post Acute Sequelae of COVID-19 · active not recruiting

Other Sona Nanotech Inc trials

Trials by the same sponsor.

NCT06870994 — Intratumoral Targeted Hyperthermia Therapy (THT) for Cutaneous Metastatic Melanoma · NA · not yet recruiting
NCT04877002 — Performance Study of SONA Saliva C-19 Rapid Test · NA · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05256589 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sona Nanotech Inc
Last refreshed: 24 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05256589.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing